0001209191-19-060108.txt : 20191211 0001209191-19-060108.hdr.sgml : 20191211 20191211191534 ACCESSION NUMBER: 0001209191-19-060108 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191209 FILED AS OF DATE: 20191211 DATE AS OF CHANGE: 20191211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: APPLE ROBERT F CENTRAL INDEX KEY: 0001054942 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 191280743 MAIL ADDRESS: STREET 1: C/O INKLINE PHARMACEUTICAL CO INC STREET 2: SENTRY PARK EAST 1720 WALTON ROAD CITY: BLUE BELL STATE: PA ZIP: 19422 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-09 0 0001016169 ANTARES PHARMA, INC. ATRS 0001054942 APPLE ROBERT F C/O ANTARES PHARMA, INC. 100 PRINCETON SOUTH, SUITE 300 EWING NJ 08628 1 1 0 0 President & CEO Common Stock 2019-12-09 4 M 0 100000 1.52 A 2005891 D Common Stock 2019-12-09 4 S 0 100000 4.6783 D 1905891 D Common Stock 2019-12-09 4 M 0 97000 1.66 A 2002891 D Common Stock 2019-12-09 4 S 0 97000 4.6228 D 1905891 D Common Stock 2019-12-09 4 M 0 110000 2.94 A 2015891 D Common Stock 2019-12-09 4 S 0 110000 4.5766 D 1905891 D Common Stock 2019-12-09 4 M 0 1000 3.96 A 1906891 D Common Stock 2019-12-09 4 S 0 1000 4.75 D 1905891 D Common Stock 2019-12-10 4 M 0 58524 3.96 A 1964415 D Common Stock 2019-12-10 4 S 0 58524 4.7563 D 1905891 D Stock Option (Right to Buy) 1.52 2019-12-09 4 M 0 100000 0.00 D 2020-11-10 Common Stock 100000 0 D Stock Option (Right to Buy) 1.66 2019-12-09 4 M 0 97000 0.00 D 2021-05-16 Common Stock 97000 0 D Stock Option (Right to Buy) 2.94 2019-12-09 4 M 0 110000 0.00 D 2022-05-16 Common Stock 110000 0 D Stock Option (Right to Buy) 3.96 2019-12-09 4 M 0 1000 0.00 D 2023-05-21 Common Stock 1000 0 D Stock Option (Right to Buy) 3.96 2019-12-10 4 M 0 58524 0.00 D 2023-05-21 Common Stock 58524 0 D The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of November 11, 2010. The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of May 17, 2011. The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of May 17, 2012. The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of May 22, 2013. The stock option exercises and sales of common stock reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. /s/ Keith Muckenhirn as attorney-in-fact for Robert Apple 2019-12-11